An endocrinologist shares Lilly's topline TRIUMPH-4 readout for its GIP, GLP-1 and glucagon triple agonist in adults with obesity or overweight.
Recap by typeshit. Post by @drpriyamvada.endo on Instagram.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
12:35
Dr. Eric Berg walks through the basics of peptides in a broad explainer. Treat any health claims as his own views.
An AI chatbot answer lays out single, dual and triple agonists, noting Lilly's retatrutide adds the glucagon receptor and is still investigational.
Loading…